Efficacy and Safety of Letrozole versus Clomiphene Citrate for Ovulation Induction in Infertile Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Abstract
Background: Clomiphene citrate was the standard first-line oral agent for ovulation induction in women with polycystic ovary syndrome (PCOS). Letrozole is now recommended as first-line pharmacological treatment for anovulatory infertility in women with PCOS and no other infertility factors. An updated appraisal of efficacy, safety and the limitations of the available trials remains relevant.
Objective: To compare the efficacy and safety of letrozole and clomiphene citrate for ovulation induction in infertile women with PCOS.
Methods: Randomized controlled trials comparing letrozole with clomiphene citrate, each given alone with or without an hCG trigger, timed intercourse or intrauterine insemination, were eligible. Reports were identified through web, publisher, journal and registry searching up to 23 October 2026. One reviewer selected studies, extracted data and assessed risk of bias with RoB 2. Risk ratios (RR) were pooled with a random-effects model. Certainty of evidence was rated with GRADE.
Results: Of 49 reports assessed, 18 trials (3,031 women) were included, and 15 trials (2,769 women) contributed to meta-analyses. Letrozole increased live birth (5 trials, 1,613 women; RR 1.54, 95% CI 1.30 to 1.82; I² = 0%; moderate certainty), pregnancy (13 trials, 2,603 women; RR 1.60, 1.44 to 1.79; I² = 0%; low certainty) and ovulation (8 trials, 1,222 women; RR 1.30, 1.14 to 1.48; I² = 57%; low certainty). Miscarriage per woman randomized was higher with letrozole (5 trials; RR 1.46, 1.03 to 2.08; low certainty), but miscarriage per pregnancy showed no clear difference (RR 0.98, 0.71 to 1.35). The effect on multiple pregnancy was very uncertain (RR 1.13, 0.16 to 7.99; very low certainty), and no trial that reported ovarian hyperstimulation syndrome recorded a case. Results for live birth were similar when restricted to the two trials at low risk of bias (RR 1.42, 1.14 to 1.76). The multiple-pregnancy synthesis is incomplete, and reconstruction-based sensitivity grouping requires verification.
Conclusions: In infertile women with PCOS, the current analysis suggests that letrozole probably increases live birth compared with clomiphene citrate, with about 107 more live births per 1,000 women treated. Miscarriage per pregnancy showed no clear between-group difference, although this conditional comparison does not establish equivalent safety. The findings are consistent with guideline recommendations for letrozole as first-line oral treatment for anovulatory infertility in PCOS when no other infertility factors are present.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Authors

This work is licensed under a Creative Commons Attribution 4.0 International License.



